Clinical Trial Update: RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating a receptor for advanced glycation end products (RAGE) inhibitor to decrease cardiotoxicity in women with early breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cancer-related Cognitive Decline

Drugs mentioned

• RAGE inhibitor (investigational) (RAGE inhibitor)

Snippet

Sponsor: Georgetown University | Conditions: Cancer Related Cognitive Decline, Non-metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING